IDEXX Cancer Dx testing
Resources
Downloadable medical resources.
Having the medical materials at hand makes it easy for your practice to have the information you need, when you need it. Here, you’ll find links to the IDEXX Cancer Dx testing algorithm, white paper, and clinical reference guide.
Clinical reference guide
An easy, convenient way to learn about cancer prevalence, risk factors, how to use IDEXX Cancer Dx testing, and more.
Algorithm
Everything you need to know to get started and up to speed on IDEXX Cancer Dx testing.
Getting started with IDEXX Cancer Dx testing.
This is where you’ll find the onboarding guide, and guides for setting up tests in Cornerstone, Neo, and ezyVet software.
Quick start guide
Step-by-step instructions to start using IDEXX Cancer Dx testing.
Ordering and setting up tests in Cornerstone
Ordering and setting up tests in Neo
Ordering and setting up tests in ezyVet
Lymphoma resources on The Vetiverse
Lymphoma in Dogs 101: A Guide for Veterinarians
From Breed to Environment: Key Risk Factors for Canine Cancer
How to Talk to Pet Owners About Cancer Including Top Questions to Answer
Dog Breeds and Cancer: Which Dogs Have Increased Risk?
How to Distinguish B-Cell Lymphoma from T-Cell Lymphoma in Dogs
FAQs
IDEXX Cancer Dx testing provides accurate detection of biomarkers specific for lymphoma in canine serum and whole blood. B-cell vs. T-cell phenotype classification will be provided with positive results as available at no additional cost.
IDEXX Cancer Dx testing provides two indications, both for canine lymphoma:
- Aid in diagnosis: IDEXX Cancer Dx testing can be performed on dogs in which lymphoma is suspected, whether that be due to a physical examination abnormality, blood work abnormality, or report of illness or change in behaviour at home.
- Screening: In early studies, IDEXX Cancer Dx testing has the potential to detect lymphoma up to 2 months in advance of the onset of clinical signs.¹ This would be most appropriately used in senior dogs (aged 7 years and older) and at-risk breeds aged 4 and older.
At-risk dogs include dogs of all breeds aged 7 or older and dogs of breeds at increased risk for cancer aged 4 or older. These dog breeds have an increased risk for lymphoma: beagle, Bernese mountain dog, boxer, bullmastiff, Doberman pinscher, English bulldog, flat-coated retriever, French bulldog, golden retriever, Labrador retriever, miniature schnauzer, rottweiler, and Scottish terrier. Dog breeds at increased risk for cancer include those above along with these: Boston terrier, Chinese pug, German shepherd, Irish wolfhound, Pembroke Welsh corgi, Rhodesian ridgeback, Scottish deerhound, shar-pei, Siberian husky, and weimaraner.
The specimen requirement for the IDEXX Cancer Dx Test is 2 mL of serum and 1 mL of EDTA whole blood (LTT) when run as a standalone, add-on, or in a profile. When included in a profile with chemistry and CBC, the IDEXX Cancer Dx Test is run using a portion of the 2 mL serum and 1 mL EDTA whole blood specimens required for standard biochemistry and hematology testing. A separate pair of tubes are not necessary.
Results will be reported as either “consistent with lymphoma” or “not consistent with lymphoma.” If a result is unable to be obtained on the specimen submitted, the customer will be notified appropriately within their results view.